(RS)-nomifensine
Nomifensine, formerly sold under the brand names Merital and Alival, is a norepinephrine–dopamine reuptake inhibitor (NDRI) drug that was developed in the 1960s by Hoechst AG (now Sanofi-Aventis), who then test marketed it in the United States.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 462262394
- Drug.IUPAC_name
- (±)-2-Methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine
- Drug.image
- Nomifensine.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200
- Drug.caption
- Above: molecular structure of nomifensine Below: 3D representation of a nomifensine molecule
- Drug.image2
- Nomifensine 3D.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Merital, Alival
- Drug.legal_BR
- C1
Article
9 sectionsContents
- Medical uses
- Adverse effects
- Withdrawal from market
- Synthesis
- Research
- Motivational disorders
- Wakefulness
- See also
- References
Nomifensine, formerly sold under the brand names Merital and Alival, is a norepinephrine–dopamine reuptake inhibitor (NDRI) drug that was developed in the 1960s by Hoechst AG (now Sanofi-Aventis), who then test marketed it in the United States.
Nomifensine was considered an effective antidepressant that lacked sedative effects. It did not interact significantly with alcohol and lacked anticholinergic effects. No withdrawal symptoms were seen after 6 months treatment. The drug was, however, considered not suitable for agitated patients as it presumably made agitation worse. In January 1986 the drug was withdrawn by its manufacturers for safety reasons.
Connections
Categories
AnilinesAntidepressantsDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs with non-standard legal statusHepatotoxinsNorepinephrine–dopamine reuptake inhibitorsPro-motivational agentsStimulantsTetrahydroisoquinolinesWakefulness-promoting agentsWithdrawn drugs